

麻疹

父母须知



PiC PHYSICIANS FOR INFORMED CONSENT

网站提供西班牙语/网站提供西班牙语
physiciansforinformedconsent.org/麻疹



1. 什么是麻疹？

麻疹是一种自限性的儿童病毒感染。

- 麻疹前驱(初始)期的病症包括咳嗽、流鼻涕、眼部刺激及发热，在发病4-10天后会出现全身性皮疹。¹
- 麻疹在前驱期和出疹后的3-4天内具有传染性。¹
- 大多数麻疹病例是良性的，未向公共卫生部门报告。²
- 在麻疹疫苗接种计划开始推行之前，几乎每个人都会得麻疹，15岁以后会终生免疫。¹
- 在极个别情况下，麻疹会导致脑损伤和死亡。^{3,4}

美国疾病控制和预防中心(CDC)是根据报告的病例发布麻疹病例死亡率的。不过，近90%的麻疹病例是良性的，且未报告给疾病预防控制中心。²根据报告的病例(仅占所有病例的10%)计算所得的病死率比实际全体病例的病死率高10倍。此处的数据分析是基于全部麻疹病例的(包括已报告及未报告的)。



2. 有什么风险？

在现代美国，很少有人因麻疹而导致终生残疾或死亡。1900年至1963年期间，由于生活条件、营养和医疗水平的提高，人口中的麻疹死亡率从每10万病例中13.³人致死下降至每10万病例中0.2人致死——下降了98% (图1)。^{2,5}营养不良，尤其是维生素A缺乏，是导致不发达国家每年约90000例麻疹病例死亡的主要原因。⁶在美国和其他发达国家，75-92%的住院治疗麻疹病例是由于维生素A缺乏。^{7,8}

麻疹的研究资料和国家追踪记录中记录了以下内容：

- 万分之一，即0.01%的麻疹病例会致死。³
- 万分之三至万分之三点五，即0.03-0.035%的麻疹病例会导致癫痫。⁹
- 两万分之一，即0.005%的麻疹病例会导致麻疹脑炎。⁴
- 八万分之一，即0.00125%的病例因引发麻疹脑炎导致终生残疾。⁴
- 千分之七，即0.7%的病例会入院治疗。¹⁰
- 百万分之六至百万分之二十二，即0.0006-0.0022%的病例会导致亚急性硬化性全脑炎(SSPE)。¹¹

1900-1963年期间，麻疹死亡率下降^{2,5}




图 1：麻疹疫苗开始推行前，从1900年至1963年，麻疹死亡率下降了98%。



3. 麻疹有哪些治疗方法？

由于几乎所有麻疹病例的病症都能自行消退，所以通常只需要辅助性治疗。因此，治疗方案包括以下内容：

- 休息
- 补水
- 高剂量维生素A¹²
- 免疫球蛋白（可用于免疫功能低下的患者，如化疗患者）¹³



维生素 A

世界卫生组织 (WHO) 推荐重症麻疹病例使用高剂量维生素A进行治疗，50000-200000国际单位(IU)，连续两天口服。¹³



4. 得麻疹有什么好处吗？

有研究表明，自然获得性麻疹感染有助于降低患霍奇金淋巴瘤和非霍奇金淋巴瘤的风险，同时降低患花粉热、湿疹和哮喘等异位性疾病的风险。¹⁴⁻¹⁸此外，麻疹感染者成年后

心血管疾病的死亡风险较低。¹⁹而且，自然获得麻疹感染的母亲所生的婴儿通过母体获得的免疫力，相较于接种疫苗的母亲所生的婴儿，拥有更长的麻疹免疫有效期。²⁰



5. 如何看待麻疹疫苗？

麻疹疫苗是从1963年开始在美国推行的，现在仅作为麻疹、腮腺炎和风疹 (MMR) 疫苗的组成之一。它大大降低了麻疹的发病率；然而，已经出现过疫苗无效的报告，疫苗无法预防所有接种者免于麻疹感染。²¹ 制造商的药品说明书包含关于疫苗的成分、不良反应和疫苗评估的信息。例如，“M-M-R II疫苗尚未进行是否有可能致癌、引发病变或损害生育能力的评估。”¹¹此外，尚无证据证明 MMR 疫苗导致永久性伤害和死亡的风险低于麻疹（图2）^{22, 23}

10岁以下儿童的麻疹死亡率及主要死因(每10万人)²²⁻²⁵




图 2：该图显示了推行疫苗之前，在麻疹还是一种常见的儿童病毒感染时，当时的麻疹死亡率，并将其与今天10岁以下儿童的主要死亡原因进行比较。结果是：在推行疫苗接种之前，10岁以下儿童的麻疹死亡率为10万分之0.9。2015年，凶杀导致的死亡率为10万分之1.3，其次是癌症（10万分之2.0）、婴儿猝死综合征（10万分之3.9）、意外伤害（10万分之8.2）和先天性异常（10万分之13.6）。因为现有的研究无法做出精确的计算，所以MMR疫苗导致死亡或永久性伤害的几率不详。^{22, 23}

所有参考文献及麻疹疫苗风险声明 (VRS) 均可见于 physiciansforinformedconsent.org/麻疹。

这些说明仅供参考，不应被视为个人医疗建议使用。

参考文献

1. Centers for Disease Control. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Hamborsky J, Kroger A, Wolfe S, editors. Washington D.C.: Public Health Foundation; 2015. 209-15.
2. **Between 1959 and 1962, annually there were about 4 million cases, of which 440,000 (11%) were reported.**
 - Centers for Disease Control. Epidemiology and prevention of vaccine-preventable diseases. 13th ed. Hamborsky J, Kroger A, Wolfe S, editors. Washington D.C.: Public Health Foundation; 2015. Appendix E3.
 - Centers for Disease Control. Measles prevention: recommendations of the Immunization Practices Advisory Committee (ACIP). Morbidity and Mortality Weekly Report. 1989; 38(S-9):1.
3. **Between 1959 and 1962, annually there were 400 measles deaths out of 4 million cases, about 1 in 10,000 cases.**
 - Same sources as reference 2.
 - Langmuir AD, Henderson DA, Serfling RE, Sherman IL. The importance of measles as a health problem. Am J Public Health Nations Health. 1962 Feb;52(2)Suppl:1-4.
4. **Measles surveillance in the 1980s and 1990s showed that there are half as many cases of measles encephalitis as there are measles deaths, 1 in 20,000 cases (50% of 1 in 10,000 cases of death). Of these cases, 25% (1 in 80,000 cases) result in residual neurological injury.**
 - Same sources as references 1 and 3.
5. Grove RD; Hetzel AM; U.S. Department of Health, Education, and Welfare. Vital statistic rates in the United States 1940-1960. Washington D.C.: U.S. Government Printing Office;1968. 559-603.
6. **The measles case-fatality rate in underdeveloped nations, where vitamin A deficiency is prevalent, is about 3-6% of reported cases, 30 to 60 times higher than in developed countries.**
 - World Health Organization. Measles: fact sheet [updated 2017 Oct; cited 2017 Dec 7]. <http://www.who.int/mediacentre/factsheets/fs286/en>.
7. Butler JC, Havens PL, Sowell AL, Huff DL, Peterson DE, Day SE, Chusid MJ, Bennin RA, Circo R, Davis JP. Measles severity and serum retinol (vitamin A) concentration among children in the United States. Pediatrics. 1993 Jun;91(6):1177-81.
8. Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med. 1990 July;323(3):160-4.
9. **Measles surveillance in the 1980s and 1990s showed that there are 3 to 3.5 times more measles seizures than measles deaths (3 to 3.5 per 10,000 cases).**
 - Same sources as references 1 and 3.
10. **Measles surveillance in the 1980s and 1990s showed that there are about 70 times more measles hospitalizations than measles deaths (7 per 1,000 cases).**
 - Same sources as reference 3.
 - Centers for Disease Control. Current trends measles — United States, 1989 and first 20 weeks 1990, June 1990. MMWR. 1990;39(21):353-5,361-3.
11. U.S. Food and Drug Administration: M-M-R II (measles, mumps, and rubella virus vaccine live). Whitehouse Station: Merck & Co., Inc.; c1971 [cited 2017 June 21]. <https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproduct/ucm123789.pdf>.
12. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004 May 1;189 Suppl 1: S4-16.
13. California Department of Public Health. Measles investigation quicksheet. May 2011.
14. Alexander FE, Jarrett RF, Lawrence D, Armstrong AA, Freeland J, Gokhale DA, Kane E, Taylor GM, Wright DH, Cartwright RA. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer. 2000 Mar;82(5):1117-21.
15. Glaser SL, Keegan TH, Clarke CA, Trinh M, Dorfman RF, Mann RB, DiGiuseppe JA, Ambinder RF. Exposure to childhood infections and risk of Epstein-Barr virus—defined Hodgkin's lymphoma in women. Int J Cancer. 2005 Jul 1;115(4):599-605.
16. Montella M, Maso LD, Crispo A, Talamini R, Bidoli E, Grimaldi M, Giudice A, Pinto A, Franceschi S. Do childhood diseases affect NHL and HL risk? A case-control study from northern and southern Italy. Leuk Res. 2006 Aug;30(8):917-22.
17. Shaheen SO, Aaby P, Hall AJ, Barker DJ, Heyes CB, Shiell AW, Goudiaby A. Measles and atopy in Guinea-Bissau. Lancet. 1996 Jun 29;347:1792-6.
18. Rosenlund H, Bergström A, Alm JS, Swartz J, Scheynius A, van Hage M, Johansen K, Brunekreef B, von Mutius E, Ege MJ, Riedler J, Braun-Fahrlander C, Waser M, Pershagen G; PARSIFAL Study Group. Allergic disease and atopic sensitization in children in relation to measles vaccination and measles infection. Pediatrics. 2009 Mar;123(3):771-8.
19. Kubota Y, Iso H, Tamakoshi A, JACC Study Group. Association of measles and mumps with cardiovascular disease. The Japan Collaborative Cohort (JACC) study. Atherosclerosis. 2015 August;241(2):682-6.
20. Waaijenborg S, Hahné SJ, Mollema L, Smits GP, Berbers GA, van der Klis FR, de Melker HE, Wallinga J. Waning of maternal antibodies against measles, mumps, rubella, and varicella in communities with contrasting vaccination coverage. J Infect Dis. 2013 Jul;208(1):10-6.
21. Poland GA, Jacobson RM. The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines? Vaccine. 2012 Jan 5;30(2):103-4.
22. Physicians for Informed Consent. Measles – vaccine risk statement (VRS). Dec 2017. <https://www.physiciansforinformedconsent.org/measles/vrs>.
23. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database of Syst Rev. 2012 Feb 15;(2).
24. 10 leading causes of death by age group, United States—2015. Atlanta: Centers for Disease Control and Prevention [cited 2017 June 21]. https://www.cdc.gov/injury/images/lc-charts/leading_causes_of_death_age_group_2015_1050w740h.gif.
25. U.S. Department of Health, Education, and Welfare. Vital statistics of the United States 1962, volume 2—mortality, part A. Washington D.C.: U.S. Government Printing Office; 1964. 94.